PerturbFate

Scientists have developed PerturbFate, a new computational tool that identifies common control hubs shared by hundreds of cancer mutations rather than targeting each mutation individually. The system tracks how different mutations reshape cells over time to reveal convergence points in disease pathways. This breakthrough could transform treatment approaches for cancer, Alzheimer's, and other diseases driven by multiple genetic mutations.

PerturbFate, a high-throughput single-cell platform, identifies common regulatory nodes and phenotypic states linked to vemurafenib resistance in melanoma cells. The study, published in Nature, uses CRISPR interference to map convergent regulators of drug resistance in melanoma.

Researchers developed PerturbFate, a platform to track gene expression and chromatin changes in gene-edited cells. When applied to skin-cancer cells, it revealed that diverse genetic perturbations linked to tumor resistance lead to a common dedifferentiated state.